Carbamazepine uptake into rat brain following intra-olfactory transport

被引:62
作者
Barakat, NS
Omar, SA
Ahmed, AAE
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh 11495, Saudi Arabia
[2] King Saud Univ, Coll Pharm, Dept Pharmacol, Riyadh 11495, Saudi Arabia
关键词
D O I
10.1211/jpp.58.1.0008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Targeting the brain via nasal administration of drugs has been studied frequently over the last few years. In this study, a suitable gel formulation was designed to provide the absorption of a highly lipophilic drug through nasal mucosa. For this purpose, carbamazepine was chosen as the model drug. Hypromellose and Carbopol were used as mucoadhesive polymers in the formulation to increase the residence time of the gel on the mucosa. The objective of this study was to confirm the existence of a transport pathway for a drug (carbamazepine) to the brain directly from the nasal cavity, by comparing the concentration of drug in the brain after intranasal (i.n.), intravenous (i.v.), and oral (p.o.) administration. A statistically significant high level of the drug was found in the brain following intranasal administration compared with the intravenous and oral routes. These findings suggested the existence of a direct transport pathway for carbamazepine from the nasal cavity to the brain. This pathway may represent a new delivery route to the brain and central nervous system of such drugs which are needed in high and rapid concentration in the brain, especially in emergencies.
引用
收藏
页码:63 / 72
页数:10
相关论文
共 51 条
[1]  
Anand Kumar T. C., 1974, CURR SCI, V43, P435
[2]   The potential of nasal application for delivery to the central brain - a microdialysis study of fluorescein in rats [J].
Bagger, MA ;
Bechgaard, E .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 21 (2-3) :235-242
[3]   CLINICAL PHARMACOKINETICS AND PHARMACOLOGICAL EFFECTS OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE - AN UPDATE [J].
BERTILSSON, L ;
TOMSON, T .
CLINICAL PHARMACOKINETICS, 1986, 11 (03) :177-198
[4]  
Chen Xue-Qing, 1998, J Alzheimers Dis, V1, P35
[5]  
CHIEN YW, 1987, CRC CR REV THER DRUG, V4, P67
[6]  
Chou KJ, 1997, BIOPHARM DRUG DISPOS, V18, P335, DOI 10.1002/(SICI)1099-081X(199705)18:4<335::AID-BDD22>3.0.CO
[7]  
2-W
[8]   Direct nose-brain transport of benzoylecgonine following intranasal administration in rats [J].
Chow, HHS ;
Anavy, N ;
Villalobos, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (11) :1729-1735
[9]   Transfer of dopamine in the olfactory pathway following nasal administration in mice [J].
Dahlin, M ;
Bergman, U ;
Jansson, B ;
Bjork, E ;
Brittebo, E .
PHARMACEUTICAL RESEARCH, 2000, 17 (06) :737-742
[10]   Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats [J].
Dahlin, M ;
Björk, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 212 (02) :267-274